166 related articles for article (PubMed ID: 9808546)
21. Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome.
Buchholz S; Dammann E; Stadler M; Krauter J; Beutel G; Trummer A; Eder M; Ganser A
Eur J Haematol; 2012 Jan; 88(1):52-60. PubMed ID: 21883483
[TBL] [Abstract][Full Text] [Related]
22. Sequential HLA-haploidentical transplantation utilizing post-transplantation cyclophosphamide for GvHD prophylaxis in high-risk and relapsed/refractory AML/MDS.
Fraccaroli A; Prevalsek D; Fritsch S; Haebe S; Bücklein V; Schulz C; Hubmann M; Stemmler HJ; Ledderose G; Hausmann A; Schmid C; Tischer J
Am J Hematol; 2018 Dec; 93(12):1524-1531. PubMed ID: 30194866
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
[TBL] [Abstract][Full Text] [Related]
24. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
25. Post-transplant Cyclophosphamide Versus Thymoglobulin in HLA-Mismatched Unrelated Donor Transplant for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Modi D; Kondrat K; Kim S; Deol A; Ayash L; Ratanatharathorn V; Uberti JP
Transplant Cell Ther; 2021 Sep; 27(9):760-767. PubMed ID: 34174469
[TBL] [Abstract][Full Text] [Related]
26. Graft-versus-Host Disease Prophylaxis with Post-Transplantation Bendamustine in Patients with Refractory Acute Leukemia: A Dose-Ranging Study.
Moiseev I; Bondarenko S; Morozova E; Vlasova Y; Dotsenko A; Epifanovskaya O; Babenko E; Botina A; Baykov V; Surkova E; Lapin S; Beynarovich A; Borzenkova E; Golosgchapov O; Kanunnikov M; Kudyasheva O; Ovechkina V; Pirogova O; Porunova V; Rudakova T; Smikova O; Smirnova A; Afansyev B
Transplant Cell Ther; 2021 Jul; 27(7):601.e1-601.e7. PubMed ID: 33845259
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults.
Metheny L; Callander NS; Hall AC; Zhang MJ; Bo-Subait K; Wang HL; Agrawal V; Al-Homsi AS; Assal A; Bacher U; Beitinjaneh A; Bejanyan N; Bhatt VR; Bredeson C; Byrne M; Cairo M; Cerny J; DeFilipp Z; Perez MAD; Freytes CO; Ganguly S; Grunwald MR; Hashmi S; Hildebrandt GC; Inamoto Y; Kanakry CG; Kharfan-Dabaja MA; Lazarus HM; Lee JW; Nathan S; Nishihori T; Olsson RF; Ringdén O; Rizzieri D; Savani BN; Savoie ML; Seo S; van der Poel M; Verdonck LF; Wagner JL; Yared JA; Hourigan CS; Kebriaei P; Litzow M; Sandmaier BM; Saber W; Weisdorf D; de Lima M
Transplant Cell Ther; 2021 Nov; 27(11):923.e1-923.e12. PubMed ID: 34428556
[TBL] [Abstract][Full Text] [Related]
28. CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.
de Lima M; Oran B; Champlin RE; Papadopoulos EB; Giralt SA; Scott BL; William BM; Hetzer J; Laille E; Hubbell B; Skikne BS; Craddock C
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2017-2024. PubMed ID: 29933073
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors.
Shaw PJ; Kan F; Woo Ahn K; Spellman SR; Aljurf M; Ayas M; Burke M; Cairo MS; Chen AR; Davies SM; Frangoul H; Gajewski J; Gale RP; Godder K; Hale GA; Heemskerk MB; Horan J; Kamani N; Kasow KA; Chan KW; Lee SJ; Leung WH; Lewis VA; Miklos D; Oudshoorn M; Petersdorf EW; Ringdén O; Sanders J; Schultz KR; Seber A; Setterholm M; Wall DA; Yu L; Pulsipher MA
Blood; 2010 Nov; 116(19):4007-15. PubMed ID: 20671124
[TBL] [Abstract][Full Text] [Related]
30. Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC).
Pochon C; Detrait M; Dalle JH; Michel G; Dhédin N; Chalandon Y; Brissot E; Forcade E; Sirvent A; Izzadifar-Legrand F; Michallet M; Renard C; Yakoub-Agha I; Gonzales F; Bay JO; Kanold J; Cornillon J; Bulabois CE; Angoso M; Nguyen S; Balza M; Chevallier P; Rialland F; Bazarbachi A; Beguin Y; Huynh A; Ménard AL; Schneider P; Neven B; Paillard C; Raus N; Albuisson E; Remen T; Rubio MT
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2083-2097. PubMed ID: 34480598
[TBL] [Abstract][Full Text] [Related]
31. Unrelated donor bone marrow transplantation for myelodysplastic syndrome in children.
Woodard P; Carpenter PA; Davies SM; Gross TG; He W; Zhang MJ; Horn BN; Margolis DA; Perentesis JP; Sanders JE; Schultz KR; Seber A; Woods WG; Eapen M
Biol Blood Marrow Transplant; 2011 May; 17(5):723-8. PubMed ID: 20813197
[TBL] [Abstract][Full Text] [Related]
32. Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies.
Oudin C; Chevallier P; Furst S; Guillaume T; El Cheikh J; Delaunay J; Castagna L; Faucher C; Granata A; Devillier R; Chabannon C; Esterni B; Vey N; Mohty M; Blaise D
Haematologica; 2014 Nov; 99(11):1762-8. PubMed ID: 25085356
[TBL] [Abstract][Full Text] [Related]
33. Unmanipulated haploidentical hematopoietic stem cell transplantation for children with myelodysplastic syndrome.
Suo P; Wang S; Xue Y; Cheng Y; Kong J; Yan C; Zhao X; Chen Y; Han W; Xu L; Zhang X; Liu K; Zhang L; Huang X; Wang Y
Pediatr Transplant; 2020 Nov; 24(7):e13864. PubMed ID: 32985788
[TBL] [Abstract][Full Text] [Related]
34. Prospective Study of a Novel, Radiation-Free, Reduced-Intensity Bone Marrow Transplantation Platform for Primary Immunodeficiency Diseases.
Dimitrova D; Gea-Banacloche J; Steinberg SM; Sadler JL; Hicks SN; Carroll E; Wilder JS; Parta M; Skeffington L; Hughes TE; Blau JE; Broadney MM; Rose JJ; Hsu AP; Fletcher R; Nunes NS; Yan XY; Telford WG; Kapoor V; Cohen JI; Freeman AF; Garabedian E; Holland SM; Lisco A; Malech HL; Notarangelo LD; Sereti I; Shah NN; Uzel G; Zerbe CS; Fowler DH; Gress RE; Kanakry CG; Kanakry JA
Biol Blood Marrow Transplant; 2020 Jan; 26(1):94-106. PubMed ID: 31493539
[TBL] [Abstract][Full Text] [Related]
35. Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report.
Wu J; Chen Y; Hageman L; Francisco L; Ness EC; Parman M; Kung M; Watson JA; Weisdorf DJ; Snyder DS; McGlave PB; Forman SJ; Arora M; Armenian SH; Bhatia R; Bhatia S
Cancer; 2019 Nov; 125(22):4033-4042. PubMed ID: 31412155
[TBL] [Abstract][Full Text] [Related]
36. Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy.
Zuanelli Brambilla C; Lobaugh SM; Ruiz JD; Dahi PB; Goldberg AD; Young JW; Gyurkocza B; Shaffer BC; Ponce DM; Tamari R; Sanchez Escamilla M; Castillo Flores N; Politikos I; Scordo M; Shah GL; Cho C; Lin RJ; Maloy MA; Devlin SM; Jakubowski AA; Berman E; Stein EM; Papadopoulos EB; Perales MA; Tallman MS; Giralt SA; Smith M
Transplant Cell Ther; 2021 Sep; 27(9):771.e1-771.e10. PubMed ID: 34033977
[TBL] [Abstract][Full Text] [Related]
37. Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Guillaume T; Malard F; Magro L; Labopin M; Tabrizi R; Borel C; Chevallier P; Vigouroux S; Peterlin P; Garnier A; Rubio MT; Huynh A; Milpied N; Moreau P; Gaugler B; Yakoub-Agha I; Mohty M
Bone Marrow Transplant; 2019 Nov; 54(11):1815-1826. PubMed ID: 31089280
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia.
Sanders JE; Im HJ; Hoffmeister PA; Gooley TA; Woolfrey AE; Carpenter PA; Andrews RG; Bryant EM; Appelbaum FR
Blood; 2005 May; 105(9):3749-56. PubMed ID: 15637143
[TBL] [Abstract][Full Text] [Related]
39. Effects of Acute and Chronic Graft-versus-myelodysplastic Syndrome on Long-term Outcomes Following Allogeneic Hematopoietic Cell Transplantation.
Konuma T; Ishiyama K; Igarashi A; Uchida N; Ozawa Y; Fukuda T; Ueda Y; Matsuoka KI; Mori T; Katayama Y; Onizuka M; Ichinohe T; Atsuta Y;
Clin Cancer Res; 2020 Dec; 26(24):6483-6493. PubMed ID: 32895232
[TBL] [Abstract][Full Text] [Related]
40. Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome.
Mawad R; Gooley TA; Rajendran JG; Fisher DR; Gopal AK; Shields AT; Sandmaier BM; Sorror ML; Deeg HJ; Storb R; Green DJ; Maloney DG; Appelbaum FR; Press OW; Pagel JM
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1363-8. PubMed ID: 24858425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
